Evaxion Biotech AS (EVAX)
3.97
+0.06
(+1.53%)
USD |
NASDAQ |
May 02, 15:24
Evaxion Biotech Total Assets (Quarterly): 12.89M for Dec. 31, 2023
Total Assets (Quarterly) Chart
Historical Total Assets (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 12.89M |
| September 30, 2023 | 11.94M |
| June 30, 2023 | 16.75M |
| March 31, 2023 | 20.49M |
| December 31, 2022 | 22.02M |
| September 30, 2022 | 27.45M |
| June 30, 2022 | 34.00M |
| March 31, 2022 | 41.08M |
| Date | Value |
|---|---|
| December 31, 2021 | 40.16M |
| September 30, 2021 | 24.12M |
| June 30, 2021 | 27.66M |
| March 31, 2021 | 34.92M |
| December 31, 2020 | 11.96M |
| September 30, 2020 | 11.28M |
| December 31, 2019 | 11.08M |
Total Assets Definition
Assets are a main portion of the balance sheet of a company that measure things that provide economic value. A few examples of assets of a company include cash, inventories, and accounts receivable. From an accounting perspective, the balance sheet equation is Assets = Liabilities + Shareholder's Equity.
Total Assets (Quarterly) Range, Past 5 Years
11.08M
Minimum
Dec 2019
41.08M
Maximum
Mar 2022
23.19M
Average
22.02M
Median
Dec 2022
Total Assets (Quarterly) Benchmarks
| Ascendis Pharma A/S | 912.60M |
| DBV Technologies SA | 182.99M |
| Cellectis SA | 334.27M |
| Adaptimmune Therapeutics PLC | 282.62M |
| Akari Therapeutics PLC | 4.355M |
Total Assets (Quarterly) Related Metrics
| Total Liabilities (Quarterly) | 17.63M |
| Shareholders Equity (Quarterly) | -4.739M |
| Debt to Equity Ratio | -1.825 |
| Current Ratio | 1.179 |